Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome

Atherosclerosis

Volumn 199, Issue 2, 2008, Pages 415-423

  Gómez Rosso, Leonardo ^a   Benítez, María Belén ^a   Fornari, María Cecilia ^b   Berardi, Vanina ^b   Lynch, Santiago ^c   Schreier, Laura ^a   Wikinski, Regina ^a   Cuniberti, Luis ^c   Brites, Fernando ^a  

^a Laboratory of Lipids and Lipoproteins   (Argentina)

^b Bioalpha Laboratory   (Argentina)

^c FAVALORO UNIVERSITY   (Argentina)

Author keywords

Adhesion molecules; Adiponectin; Atherosclerosis; Biomarkers; Inflammation; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ALPHA4 INTEGRIN; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BIOLOGICAL MARKER; CD18 ANTIGEN; CELL ADHESION MOLECULE; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CELL INTERACTION; CELL MIGRATION; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; ENDOTHELIUM; ENZYME ACTIVITY; HEALTH STATUS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADIPONECTIN; ANTIGENS, CD18; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CHOLESTEROL, HDL; HUMANS; INSULIN; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; VASCULAR CELL ADHESION MOLECULE-1;

EID: 47849126219     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.11.007     Document Type: Article

References (57)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106:3143-421.
2. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
3. Grundy S.M., Cleeman J.I., Daniels S.R., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
4. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366 (2005) 1059-1062
5. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 (2005) 2745-2749
6. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 1769-1778
7. Deedwania P.C. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease?. Circulation 109 (2004) 2-4
8. Pouliot M.C., Despres J.P., Lemieux S., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73 (1994) 460-468
9. Gonzalez M.A., and Selwyn A.P. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 115 Suppl. 8A (2003) 99S-106S
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. Assmann G., Jabs H.U., Kohnert U., Nolte W., and Schriewer H. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clin Chim Acta 140 (1984) 77-83
12. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 28 (1982) 1379-1388
13. Bartlett G.R. Phosphorus assay in column chromatography. J Biol Chem 234 (1959) 466-468
14. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
15. Schumaker V.N., and Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol 128 (1986) 155-170
16. Noble R.P. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 9 (1968) 693-700
17. Lagrost L., Gandjini H., Athias A., Guyard-Dangremont V., Lallemant C., and Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb 13 (1993) 815-825
18. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., and Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 180 (1989) 242-247
19. Blank M.L., Hall M.N., Cress E.A., and Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasmaacetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun 113 (1983) 666-671
20. Fornari M.C., Sarto A., Berardi V.E., et al. Effect of ovaric hyper-stimulation on blood lymphocyte subpopulations, cytokines, leptin and nitrite among patients with unexplained infertility. Am J Reprod Immunol 48 (2002) 394-403
21. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 (2003) 802-809
22. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
23. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
24. Bahia L., Aguiar L.G., Villela N., et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 61 (2006) 433-440
25. Rabin K.R., Kamari Y., Avni I., Grossman E., and Sharabi Y. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 3 (2005) 465-471
26. Verges B., Petit J.M., Duvillard L., et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 26 (2006) 1364-1369
27. Kim S.M., Cho K.H., and Park H.S. Relationship between plasma adiponectin levels and the metabolic syndrome among Korean people. Endocr J 53 (2006) 247-254
28. Shaibi G.Q., Cruz M.L., Weigensberg M.J., et al. Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J Clin Endocrinol Metab (2007) [Epub ahead of print]
29. Matsushita K., Yatsuya H., Tamakoshi K., et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26 (2006) 871-876
30. Taskinen M.R. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 6 (1995) 153-160
31. Ginsberg H.N., and Huang L.S. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 7 (2000) 325-331
32. Brites F.D., Bonavita C.D., De Geitere C., et al. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 152 (2000) 181-192
33. Brites F.D., Verona J., Schreier L.E.., et al. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities inpatients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 35 (2004) 235-240
34. Yusuf S., Hawken S., Ounpuu S., et al. INTERHEART study investigators effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
35. Hattori Y., Suzuki M., Tsushima M., et al. Development of approximate formula for LDL-chol LDL-apo B and LDL-chol/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis 138 (1998) 289-299
36. McLaughlin T., Reaven G., Abbasi F., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol 96 (2005) 399-404
37. Rizzo M., and Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 23 (2007) 14-20
38. James R.W. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44 (2006) 1052-1059
39. Senti M., Tomas M., Fito M., et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 88 (2003) 5422-5426
40. Garin M.C., Kalix B., Morabia A., and James R.W. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 90 (2005) 2264-2269
41. Tsimikas S., Willerson J.T., and Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47 Suppl. (2006) C19-C31
42. Persson M., Hedblad B., Nelson J.J., and Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27 (2007) 1411-1416
43. Rizos E., Tambaki A.P., Gazi I., Tselepis A.D., and Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 203-209
44. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
45. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
46. Miller M.A., and Cappuccio F.P. Cellular adhesion molecules and their relationship with measures of obesity and metabolic syndrome in a multiethnic population. Int J Obes (Lond) 30 (2006) 1176-1182
47. Marques-Vidal P., Mazoyer E., Bongard V., et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25 (2002) 1371-1377
48. Lee W.L., Lee W.J., Chen Y.T., et al. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism 55 (2006) 1029-1034
49. Salmenniemi U., Ruotsalainen E., Pihlajamaki J., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
50. Sjögren P., Basta G., de Caterina R., et al. Markers of endothelial activity are related to components of the metabolic syndrome, but not to circulating concentrations of the advanced glycation end-product Nvarepsilon-carboxymethyl-lysine in healthy Swedish men. Atherosclerosis (2007) [Epub ahead of print]
51. Arteaga R.B., Chirinos J.A., Soriano A.O., et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 98 (2006) 70-74
52. Van Oostrom A.J., van Wijk J.P., Sijmonsma T.P., Rabelink T.J., and Castro Cabezas M. Increased expression of activation markers on monocytes and neutrophils in type 2 diabetes. Neth J Med 62 (2004) 320-325
53. Caimi G., Montana M., Ferrara F., et al. Polymorphonuclear leukocyte integrin pattern, at baseline and after activation, in type 2 diabetic subjects with macrovascular complications. Acta Diabetol 40 (2003) 14-19
54. Grykiel K., Zozulinska D., Kostrzewa A., Wiktorowicz K., and Wierusz-Wysocka B. Evaluation of expression of polymorphonuclear neutrophil surface receptors inpatients with type 1 diabetes. Pol Arch Med Wewn 105 (2001) 377-381
55. Song H., Wang L., and Hui Y. Expression of CD18 on the neutrophils of patients with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 245 (2007) 24-31
56. Sampson M.J., Davies I.R., Brown J.C., Ivory K., and Hughes D.A. Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterioscler Thromb Vasc Biol 22 (2002) 1187-1193
57. Solymoss B.C., Bourassa M.G., Campeau L., et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 93 (2004) 159-164